Aquestive Therapeutics (AQST) Stock Price & Analysis

AQST$3.91+0.34 +9.52%
Drug Manufacturers - Specialty & GenericGrowth Stock
Compare
Market cap$491.44MEnterprise value$366.46MRevenue (TTM)$48.84MMarket position—

Score

61
Neutral
Value
57
Quality
32
Growth
94

AI Analysis

Snapshot

Aquestive Therapeutics doesn’t screen as a clean setup today — Stocklytics 61/100 leaves more to prove. Under the hood: latest revenue down ~23% YoY.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

94
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

32
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Aquestive Therapeutics, Inc. (AQST) last printed $3.91. Equity value is $491.44M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$51.78M$66.92M$67.43M$52.61M$45.85M$50.83M$47.68M$50.58M$57.56M$44.55M

About

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

Aquestive Therapeutics (AQST) Stock Price & Analysis

AQST price $3.91 +0.34 +9.52%

Ticker
AQST
Price
$3.91
Change
+0.34 +9.52%
Market cap
$491.44M
Forward P/E
8.21
Dividend yield
0.00%
Beta
1.50
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
61
Value
57
Quality
32
Growth
94

Stocklytics score rationale: value 57, quality 32, growth 94.

Fair value

AQST fair value $6.06. Price $3.91. Price is 36% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 30.0, a blend of the industry median and the stock's own 10-year median. How we calculate it →

Compare AQST

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-03—-0.11—13.70M
2026-11-03-0.13-0.127.56M11.02M
2026-08-11-0.18-0.1013.82M11.42M
2026-05-13-0.07-0.1414.45M10.90M
2026-03-04-0.26-0.1313.02M13.29M
2025-11-05-0.14-0.1112.81M12.94M
2025-08-11-0.14-0.1810.00M12.20M
2025-05-12-0.24-0.178.72M12.23M
2025-03-05-0.19-0.1411.87M13.11M
2024-11-04-0.13-0.1213.54M13.13M
2024-08-06-0.03-0.1120.10M12.38M
2024-05-07-0.17-0.0912.05M12.26M
2024-03-05-0.12-0.0813.21M11.63M
2023-11-06-0.03-0.1113.00M11.63M
2023-08-07-0.10-0.1113.24M11.01M
2023-05-020.11-0.1011.13M9.92M
2023-03-07-0.23-0.2110.68M10.42M
2022-11-01-0.23-0.3011.46M11.00M
2022-08-02-0.36-0.4113.27M10.57M
2022-05-03-0.32-0.4512.27M10.13M
2022-03-08-0.38-0.4711.08M9.36M
2021-11-02-0.37-0.4013.29M11.01M
2021-08-03-0.33-0.4215.35M15.35M
2021-05-04-0.41-0.4411.12M6.24M
2021-03-09-0.60-0.467.15M—
2020-11-04-0.49-0.508.26M7.75M
2020-08-04-0.07-0.4321.68M133.15M
2020-05-05-0.49-0.528.77M8.41M
2020-03-11-0.48-0.4516.42M13.34M
2019-11-05-0.54-0.7812.42M11.58M
2019-08-06-0.82-0.6711.13M8.41M
2019-05-08-0.59-0.4912.64M10.71M
2019-03-14-0.56-0.9116.82M15.32M
2018-11-06-0.49-0.4913.27M8.91M
2018-09-04-1.90-0.2413.93M—
2018-07-260.20—23.41M—
2017-12-31-0.50—12.20M—
2017-09-300.42—27.15M—
2017-06-30-0.29—11.14M—
2017-03-31-0.07—16.44M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-11-10Daly Richard JBuy26.82K$3.5495.09K
2026-11-10Daly Richard JBuy1.20K$3.534.24K
2026-11-10Davis Matthew W.Sell5.30K$3.5218.67K
2026-11-06Daly Richard JBuy57.00K$3.61205.77K
2026-10-21Cochran JohnBuy62.23K——
2026-10-15Barber DanielSell25.00K$4.22105.60K
2026-10-15Daly Richard JOther0——
2026-09-15Barber DanielSell25.00K$4.82120.49K
2026-09-09Korczynski SherryBuy8.75K$2.6523.19K
2026-09-09Korczynski SherrySell8.75K$5.2245.67K
2026-09-09Korczynski SherrySell8.75K$2.6523.19K
2026-09-09Boyd Peter E.Buy2.29K$0.962.20K
2026-09-09Boyd Peter E.Sell2.29K$0.962.20K
2026-09-08Barber DanielBuy91.74K$0.9688.07K
2026-09-08Barber DanielSell91.74K$0.9688.07K
2026-09-03Jung CassieBuy4.59K$0.964.40K
2026-09-03Jung CassieSell4.59K$0.964.40K
2026-08-17Barber DanielSell25.00K$4.29107.17K
2026-08-14Korczynski SherrySell2.71K$4.2511.53K
2026-07-16Barber DanielSell20.37K$4.0081.51K
2026-07-15Barber DanielSell4.63K$4.0318.68K
2026-06-23Krop JulieBuy25.00K$0.7117.83K
2026-06-23Krop JulieSell25.00K$0.7117.83K
2026-06-23Krop JulieSell25.00K$5.02125.39K
2026-06-15Barber DanielSell25.00K$4.16104.01K
2026-06-10MORRIS TIMOTHY EBuy50.50K$3.99201.50K
2026-06-10Krop JulieBuy50.50K$3.99201.50K
2026-06-10Jenkins Abigail L.Sell50.50K$3.99201.50K
2026-06-10Cochran JohnBuy50.50K$3.99201.50K
2026-06-10BROWN GREGORY BBuy50.50K$3.99201.50K
2026-06-10Taglietti MarcoBuy50.50K$3.99201.50K
2026-06-08Korczynski SherrySell2.71K——
2026-05-18Zalewski Thomas A.Buy100.00K——
2026-05-18Zalewski Thomas A.Buy75.00K$4.13310.12K
2026-05-15Barber DanielSell8.26K$4.2935.41K
2026-05-15Cioffi MelinaSell1.67K$4.176.95K
2026-05-07BRAENDER LORI JSell135.69K$4.23573.97K
2026-05-05Boyd Peter E.Sell56.78K$4.18237.33K
2026-05-05Barber DanielSell335.92K$4.181.40M
2026-05-05TOTH A ERNEST JRSell92.65K$4.18387.29K
2026-05-05Jung CassieSell72.73K$4.18304.03K
2026-05-05BRAENDER LORI JSell76.15K$4.18318.29K
2026-04-02Zalewski Thomas A.Other0——
2026-03-10Boyd Peter E.Sell29.81K$4.17124.41K
2026-03-10Barber DanielSell180.68K$4.17753.97K
2026-03-10BRAENDER LORI JSell40.10K$4.17167.35K
2026-03-10Cioffi MelinaSell25.31K$4.17105.62K
2026-03-10TOTH A ERNEST JRSell58.25K$4.17243.09K
2026-03-10Korczynski SherrySell15.74K$4.1765.69K
2026-03-10Jung CassieSell45.79K$4.17191.09K
2026-03-09Boyd Peter E.Buy80.00K——
2026-03-09Boyd Peter E.Buy42.50K$4.29182.32K
2026-03-09Barber DanielBuy262.00K——
2026-03-09Barber DanielBuy523.00K$4.292.24M
2026-03-09BRAENDER LORI JBuy80.00K——
2026-03-09BRAENDER LORI JBuy50.00K$4.29214.50K
2026-03-09Cioffi MelinaBuy100.00K——
2026-03-09Cioffi MelinaBuy75.00K$4.29321.75K
2026-03-09TOTH A ERNEST JRBuy95.00K——
2026-03-09TOTH A ERNEST JRBuy70.00K$4.29300.30K
2026-03-09Korczynski SherryBuy75.00K——
2026-03-09Korczynski SherryBuy42.50K$4.29182.32K
2026-03-09Jung CassieBuy80.00K——
2026-03-09Jung CassieBuy42.50K$4.29182.32K
2026-03-09Davis Matthew W.Buy50.00K——
2026-03-09Davis Matthew W.Buy50.00K$4.29214.50K
2026-03-09Greenhawt Matthew J.Buy75.00K——
2026-03-09Greenhawt Matthew J.Buy50.00K$4.29214.50K
2026-03-02Greenhawt Matthew J.Other0——
2025-12-04Boyd Peter E.Buy20.00K——
2025-12-02Cioffi MelinaSell2.08K$5.9312.35K
2025-11-10Davis Matthew W.Buy50.00K——
2025-11-10Davis Matthew W.Buy50.00K$5.58279.00K
2025-11-03Davis Matthew W.Other0——
2025-10-15Jung CassieBuy25.00K$3.1077.57K
2025-10-15Jung CassieSell67.58K$7.01473.70K
2025-10-15Jung CassieSell25.00K$3.1077.57K
2025-10-15Kraus Carl NSell20.27K$7.00141.90K
2025-10-15Boyd Peter E.Sell10.00K$7.0070.00K
2025-09-26Barber DanielSell91.34K$6.03551.19K
2025-09-26Boyd Peter E.Sell10.00K$6.3063.00K
2025-09-19Barber DanielSell400$6.002.40K
2025-09-05Boyd Peter E.Sell15.00K$5.3079.50K
2025-09-04Jung CassieBuy25.00K$0.7117.66K
2025-09-04Jung CassieBuy25.00K$3.1578.75K
2025-09-04Jung CassieSell62.18K$5.00310.90K
2025-09-04Jung CassieSell25.00K$0.7117.66K
2025-09-04Jung CassieSell25.00K$3.1578.75K
2025-08-14Korczynski SherryBuy25.00K——
2025-08-09Kraus Carl NSell10.82K$3.9042.19K
2025-06-11BROWN GREGORY BBuy42.00K$3.41143.22K
2025-06-11Krop JulieBuy42.00K$3.41143.22K
2025-06-11MORRIS TIMOTHY EBuy42.00K$3.41143.22K
2025-06-11Jenkins Abigail L.Sell42.00K$3.41143.22K
2025-03-07Barber DanielBuy293.10K——
2025-03-07Boyd Peter E.Buy60.00K——
2025-03-07Jung CassieBuy60.00K——
2025-03-07TOTH A ERNEST JRBuy82.50K——
2025-03-07Korczynski SherryBuy67.50K——
2025-03-07BRAENDER LORI JBuy82.50K——

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 144, holders -51 vs prior quarter. Ownership 39.68%.

HolderSharesChangeChange %Value
BRATTON CAPITAL MANAGEMENT, L.P.9.81M00.00%45.42M
BLACKROCK, INC.8.21M143.99K+1.78%38.03M
VANGUARD CAPITAL MANAGEMENT LLC4.78M199.67K+4.36%22.15M
STATE STREET CORP3.48M553.37K+18.90%16.12M
FEDERATED HERMES, INC.3.20M85.30K+2.74%14.81M
GEODE CAPITAL MANAGEMENT, LLC2.90M272.75K+10.40%13.41M
PROPEL BIO MANAGEMENT, LLC278.72K-1.16M-80.68%8.61M
HRT FINANCIAL LP1.80M1.46M+422.51%8.34M
BLUE OWL CAPITAL HOLDINGS LP1.39M447.70K+47.48%6.44M
JANNEY MONTGOMERY SCOTT LLC1.11M2.00K+0.18%5.13M
BARCLAYS PLC1.05M54.97K+5.52%4.87M
COMMONWEALTH EQUITY SERVICES, LLC1.02M-25.19K-2.41%4.73M
VANGUARD FIDUCIARY TRUST CO757.82K106.61K+16.37%3.51M
VANGUARD PORTFOLIO MANAGEMENT LLC743.54K9.30K+1.27%3.44M
WASATCH ADVISORS LP648.17K-737.67K-53.23%3.00M
MORGAN STANLEY615.76K-42.85K-6.51%2.85M
UBS GROUP AG603.84K145.42K+31.72%2.80M
RENAISSANCE TECHNOLOGIES LLC558.47K142.22K+34.17%2.59M
AWM INVESTMENT COMPANY, INC.475.40K00.00%2.20M
JANE STREET GROUP, LLC400.00K-37.49K-8.57%1.85M
BNP PARIBAS FINANCIAL MARKETS363.19K-431.49K-54.30%1.68M
JANE STREET GROUP, LLC363.00K-74.50K-17.03%1.68M
STIFEL FINANCIAL CORP359.12K-2.78K-0.77%1.66M
BANK OF NEW YORK MELLON CORP280.12K4.57K+1.66%1.30M
SIMPLIFY ASSET MANAGEMENT INC.278.72K00.00%1.29M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener